Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

Phase 1 Trials of anti-ENPP3 antibody drug conjugates in advanced refractory renal cell carcinomas.

Thompson JA, Motzer RJ, Molina AM, Choueiri TK, Heath EI, Redman BG, Sangha RS, Ernst DS, Pili R, Kim SK, Reyno L, Wiseman A, Trave F, Anand B, Morrison K, Doñate F, Kollmannsberger C.

Clin Cancer Res. 2018 May 30. pii: clincanres.0481.2018. doi: 10.1158/1078-0432.CCR-18-0481. [Epub ahead of print]

PMID:
29848572
2.

Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Motzer RJ, Jonasch E, Agarwal N, Bhayani S, Bro WP, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Fishman M, Gallagher TH, Gore JL, Hancock SL, Harrison MR, Kim W, Kyriakopoulos C, LaGrange C, Lam ET, Lau C, Michaelson MD, Olencki T, Pierorazio PM, Plimack ER, Redman BG, Shuch B, Somer B, Sonpavde G, Sosman J, Dwyer M, Kumar R.

J Natl Compr Canc Netw. 2017 Jun;15(6):804-834. doi: 10.6004/jnccn.2017.0100.

PMID:
28596261
3.

Dorsal Muscle Attenuation May Predict Failure to Respond to Interleukin-2 Therapy in Metastatic Renal Cell Carcinoma.

Otemuyiwa B, Derstine BA, Zhang P, Wong SL, Sabel MS, Redman BG, Wang SC, Alva AS, Davenport MS.

Acad Radiol. 2017 Sep;24(9):1094-1100. doi: 10.1016/j.acra.2017.03.003. Epub 2017 Mar 22.

PMID:
28341412
4.

Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial.

George S, Motzer RJ, Hammers HJ, Redman BG, Kuzel TM, Tykodi SS, Plimack ER, Jiang J, Waxman IM, Rini BI.

JAMA Oncol. 2016 Sep 1;2(9):1179-86. doi: 10.1001/jamaoncol.2016.0775.

5.

Use of Preoperative PET/CT Staging in Sentinel Lymph Node-Positive Melanoma.

Scheier BY, Lao CD, Kidwell KM, Redman BG.

JAMA Oncol. 2016 Jan;2(1):136-7. doi: 10.1001/jamaoncol.2015.3664. No abstract available.

PMID:
26401901
6.

Testicular Cancer, Version 2.2015.

Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Shuch B, Sircar K, Somer B, Wilder RB, Dwyer M, Kumar R.

J Natl Compr Canc Netw. 2015 Jun;13(6):772-99.

PMID:
26085393
7.

Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non-V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team.

LoRusso PM, Boerner SA, Pilat MJ, Forman KM, Zuccaro CY, Kiefer JA, Liang WS, Hunsberger S, Redman BG, Markovic SN, Sekulic A, Bryce AH, Joseph RW, Cowey CL, Fecher LA, Sosman JA, Chapman PB, Schwartz GK, Craig DW, Carpten JD, Trent JM.

Mol Cancer Ther. 2015 Aug;14(8):1962-71. doi: 10.1158/1535-7163.MCT-15-0153. Epub 2015 Jun 10.

8.

Kidney cancer, version 3.2015.

Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Shuch B, Sircar K, Somer B, Wilder RB, Dwyer M, Kumar R; National comprehensive cancer network.

J Natl Compr Canc Netw. 2015 Feb;13(2):151-9.

PMID:
25691606
9.

A phase 2, multicenter, open-label study of sepantronium bromide (YM155) plus docetaxel in patients with stage III (unresectable) or stage IV melanoma.

Kudchadkar R, Ernst S, Chmielowski B, Redman BG, Steinberg J, Keating A, Jie F, Chen C, Gonzalez R, Weber J.

Cancer Med. 2015 May;4(5):643-50. doi: 10.1002/cam4.363. Epub 2014 Dec 23.

10.

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.

Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, Vaishampayan UN, Drabkin HA, George S, Logan TF, Margolin KA, Plimack ER, Lambert AM, Waxman IM, Hammers HJ.

J Clin Oncol. 2015 May 1;33(13):1430-7. doi: 10.1200/JCO.2014.59.0703. Epub 2014 Dec 1.

11.

Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group.

Flaherty LE, Othus M, Atkins MB, Tuthill RJ, Thompson JA, Vetto JT, Haluska FG, Pappo AS, Sosman JA, Redman BG, Moon J, Ribas A, Kirkwood JM, Sondak VK.

J Clin Oncol. 2014 Nov 20;32(33):3771-8. doi: 10.1200/JCO.2013.53.1590. Epub 2014 Oct 20.

12.

Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933.

Lee SM, Moon J, Redman BG, Chidiac T, Flaherty LE, Zha Y, Othus M, Ribas A, Sondak VK, Gajewski TF, Margolin KA.

Cancer. 2015 Feb 1;121(3):432-440. doi: 10.1002/cncr.29055. Epub 2014 Sep 23.

13.

Retrospective analysis of the safety and efficacy of high-dose interleukin-2 after prior tyrosine kinase inhibitor therapy in patients with advanced renal cell carcinoma.

Lam ET, Wong MK, Agarwal N, Redman BG, Logan T, Gao D, Flaig TW, Lewis K, Poust J, Monk P, Jarkowski A, Sendilnathan A, Bolden M, Kuzel TM, Olencki T.

J Immunother. 2014 Sep;37(7):360-5. doi: 10.1097/CJI.0000000000000044. Erratum in: J Immunother. 2014 Nov-Dec;37(9):468.

14.

Kidney cancer, version 2.2014.

Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Sircar K, Somer B, Wang J, Wilder RB, Dwyer MA, Kumar R; Natiomal compresensive cancer networks.

J Natl Compr Canc Netw. 2014 Feb;12(2):175-82.

PMID:
24586079
15.

Concurrent whole brain radiotherapy and bortezomib for brain metastasis.

Lao CD, Friedman J, Tsien CI, Normolle DP, Chapman C, Cao Y, Lee O, Schipper M, Van Poznak C, Hamstra D, Lawrence T, Hayman J, Redman BG.

Radiat Oncol. 2013 Aug 21;8:204. doi: 10.1186/1748-717X-8-204.

16.

Molecular diagnostics of melanoma fine-needle aspirates: a cytology-histology correlation study.

Bernacki KD, Betz BL, Weigelin HC, Lao CD, Redman BG, Knoepp SM, Roh MH.

Am J Clin Pathol. 2012 Nov;138(5):670-7. doi: 10.1309/AJCPEQJW3PLOOZTC.

PMID:
23086767
17.

Testicular cancer.

Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Buyyounouski MK, Carducci MA, Chang SS, Choueiri TK, Gupta S, Hancock SL, Hudes GR, Jonasch E, Kuzel TM, Lau C, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Ratliff TW, Redman BG, Robertson CN, Ryan CJ, Sheinfeld J, Wang J, Wilder RB; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2012 Apr;10(4):502-35. No abstract available.

PMID:
22491049
18.

Kidney cancer.

Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Carducci MA, Chang SS, Choueiri TK, Hancock SL, Hudes GR, Jonasch E, Josephson D, Kuzel TM, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Ratliff TW, Redman BG, Robertson CN, Ryan CJ, Sheinfeld J, Spiess PE, Wang J, Wilder RB; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2011 Sep 1;9(9):960-77. No abstract available. Erratum in: J Natl Compr Canc Netw. 2011 Nov 1;9(11):xlv.

PMID:
21917622
19.

Immunotherapy of kidney cancer.

Grivas PD, Redman BG.

Curr Clin Pharmacol. 2011 Aug;6(3):151-63. Review.

PMID:
21827390
20.

A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430.

Sosman JA, Moon J, Tuthill RJ, Warneke JA, Vetto JT, Redman BG, Liu PY, Unger JM, Flaherty LE, Sondak VK.

Cancer. 2011 Oct 15;117(20):4740-06. doi: 10.1002/cncr.26111. Epub 2011 Mar 31.

21.

Initial patterns of care with oral targeted therapies for patients with renal cell carcinoma.

Filson CP, Redman BG, Dunn RL, Miller DC.

Urology. 2011 Apr;77(4):825-830.e1. doi: 10.1016/j.urology.2010.11.003. Epub 2011 Jan 22.

22.

Phase I/II trial of sunitinib plus gefitinib in patients with metastatic renal cell carcinoma.

Motzer RJ, Hudes GR, Ginsberg MS, Baum MS, Harmon CS, Kim ST, Chen I, Redman BG.

Am J Clin Oncol. 2010 Dec;33(6):614-8. doi: 10.1097/COC.0b013e3181c4454d.

PMID:
20142724
23.

NCCN clinical practice guidelines in oncology: kidney cancer.

Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, Choueiri TK, Figlin RA, Fishman M, Hancock SL, Hudes GR, Jonasch E, Kessinger A, Kuzel TM, Lange PH, Levine EG, Margolin KA, Michaelson MD, Olencki T, Pili R, Redman BG, Robertson CN, Schwartz LH, Sheinfeld J, Wang J.

J Natl Compr Canc Netw. 2009 Jun;7(6):618-30. No abstract available.

PMID:
19555584
24.

NCCN clinical practice guidelines in oncology: testicular cancer.

Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, Choueiri TK, Figlin RA, Fishman M, Hancock SL, Hudes GR, Jonasch E, Kessinger A, Kuzel TM, Lange PH, Levine EG, Margolin KA, Michaelson MD, Olencki T, Pili R, Redman BG, Robertson CN, Schwartz LH, Sheinfeld J, Wang J.

J Natl Compr Canc Netw. 2009 Jun;7(6):672-93. No abstract available.

PMID:
19555582
25.

Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma.

Redman BG, Chang AE, Whitfield J, Esper P, Jiang G, Braun T, Roessler B, Mulé JJ.

J Immunother. 2008 Jul-Aug;31(6):591-8. doi: 10.1097/CJI.0b013e31817fd90b.

26.

Interleukin-21 augments the efficacy of T-cell therapy by eliciting concurrent cellular and humoral responses.

Iuchi T, Teitz-Tennenbaum S, Huang J, Redman BG, Hughes SD, Li M, Jiang G, Chang AE, Li Q.

Cancer Res. 2008 Jun 1;68(11):4431-41. doi: 10.1158/0008-5472.CAN-07-5530.

27.

Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma.

Thompson JA, Curti BD, Redman BG, Bhatia S, Weber JS, Agarwala SS, Sievers EL, Hughes SD, DeVries TA, Hausman DF.

J Clin Oncol. 2008 Apr 20;26(12):2034-9. doi: 10.1200/JCO.2007.14.5193. Epub 2008 Mar 17.

PMID:
18347008
28.

The times they are a-changin' (Bob Dylan, 1964).

Bradley DA, Redman BG.

Cancer. 2007 Dec 1;110(11):2366-9. No abstract available.

29.

Sunitinib efficacy against advanced renal cell carcinoma.

Motzer RJ, Michaelson MD, Rosenberg J, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Wilding G.

J Urol. 2007 Nov;178(5):1883-7. Epub 2007 Sep 17.

PMID:
17868732
30.

Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinoma.

Mackler NJ, Pienta KJ, Dunn RL, Cooney KA, Redman BG, Olson KB, Fardig JE, Smith DC.

Clin Genitourin Cancer. 2007 Jun;5(5):318-22.

PMID:
17645828
31.

Kidney cancer. Clinical practice guidelines in oncology.

Motzer RJ, Bolger GB, Boston B, Carducci MA, Fishman M, Hancock SL, Hauke RJ, Hudes GR, Jonasch E, Kantoff P, Kuzel TM, Lange PH, Levine EG, Logothetis C, Margolin KA, Pohar K, Redman BG, Robertson CN, Samlowski WE, Sheinfeld J; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2006 Nov;4(10):1072-81. No abstract available.

PMID:
17112454
32.

Testicular cancer. Clinical practice guidelines in oncology.

Motzer RJ, Bolger GB, Boston B, Carducci MA, Fishman M, Hancock SL, Hauke RJ, Hudes GR, Jonasch E, Kantoff P, Kuzel TM, Lange PH, Levine EG, Logothetis C, Margolin KA, Pohar KS, Redman BG, Robertson CN, Samlowski WE, Sheinfeld J; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2006 Nov;4(10):1038-58. No abstract available.

PMID:
17112452
33.

Sunitinib in patients with metastatic renal cell carcinoma.

Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD.

JAMA. 2006 Jun 7;295(21):2516-24.

PMID:
16757724
34.

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.

Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI.

J Clin Oncol. 2006 Jan 1;24(1):16-24. Epub 2005 Dec 5.

PMID:
16330672
35.

Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study.

Vaishampayan UN, Faulkner JR, Small EJ, Redman BG, Keiser WL, Petrylak DP, Crawford ED.

Cancer. 2005 Oct 15;104(8):1627-32.

36.

Kidney cancer. Clinical practice guidelines.

Motzer RJ, Carducci MA, Fishman M, Hancock SL, Hauke RJ, Hudes GR, Kantoff P, Kuzel TM, Lange PH, Levine EG, Logothetis C, Margolin KA, Pili R, Pohar KS, Redman BG, Richey S, Robertson CN, Samlowski WE, Sheinfeld J, Urban DA; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2005 Jan;3(1):84-93. No abstract available.

PMID:
19813325
37.

Testicular cancer. Clinical practice guidelines.

Motzer RJ, Bahnson RR, Boston B, Carducci MA, Fishman M, Hancock SL, Hauke RJ, Hudes GR, Kantoff P, Kuzel TM, Lange PH, Levine EG, Logothetis C, Margolin KA, Redman BG, Richey S, Robertson CN, Samlowski WE, Sheinfeld J, Urban DA; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2005 Jan;3(1):52-76. No abstract available.

PMID:
19813323
38.

Evaluation of staging chest radiographs and serum lactate dehydrogenase for localized melanoma.

Wang TS, Johnson TM, Cascade PN, Redman BG, Sondak VK, Schwartz JL.

J Am Acad Dermatol. 2004 Sep;51(3):399-405.

PMID:
15337983
39.

Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen-independent prostate carcinoma.

Hellerstedt B, Pienta KJ, Redman BG, Esper P, Dunn R, Fardig J, Olson K, Smith DC.

Cancer. 2003 Oct 15;98(8):1603-10.

40.

Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial.

Clark JI, Atkins MB, Urba WJ, Creech S, Figlin RA, Dutcher JP, Flaherty L, Sosman JA, Logan TF, White R, Weiss GR, Redman BG, Tretter CP, McDermott D, Smith JW, Gordon MS, Margolin KA.

J Clin Oncol. 2003 Aug 15;21(16):3133-40. Epub 2003 Jun 16.

PMID:
12810695
41.

Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer.

Redman BG, Esper P, Pan Q, Dunn RL, Hussain HK, Chenevert T, Brewer GJ, Merajver SD.

Clin Cancer Res. 2003 May;9(5):1666-72.

42.

Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer.

Chang AE, Li Q, Jiang G, Sayre DM, Braun TM, Redman BG.

J Clin Oncol. 2003 Mar 1;21(5):884-90.

PMID:
12610189
43.

Advanced renal cell carcinoma.

Redman BG, Chang AE.

Curr Treat Options Oncol. 2000 Dec;1(5):417-22. Review.

PMID:
12057149
44.

Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group.

Sondak VK, Liu PY, Tuthill RJ, Kempf RA, Unger JM, Sosman JA, Thompson JA, Weiss GR, Redman BG, Jakowatz JG, Noyes RD, Flaherty LE.

J Clin Oncol. 2002 Apr 15;20(8):2058-66.

PMID:
11956266
45.

A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer.

Chang AE, Redman BG, Whitfield JR, Nickoloff BJ, Braun TM, Lee PP, Geiger JD, Mulé JJ.

Clin Cancer Res. 2002 Apr;8(4):1021-32.

46.

Local administration of dendritic cells inhibits established breast tumor growth: implications for apoptosis-inducing agents.

Candido KA, Shimizu K, McLaughlin JC, Kunkel R, Fuller JA, Redman BG, Thomas EK, Nickoloff BJ, Mulé JJ.

Cancer Res. 2001 Jan 1;61(1):228-36.

47.

Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point.

Small EJ, Lew D, Redman BG, Petrylak DP, Hammond N, Gross HM, Eastham JA, Crawford ED.

J Clin Oncol. 2000 Jul;18(13):2537-44.

PMID:
10893284
48.

Potentiation of immunologic responsiveness to dendritic cell-based tumor vaccines by recombinant interleukin-2.

Shimizu K, Fields RC, Redman BG, Giedlin M, Mulé JJ.

Cancer J Sci Am. 2000 Feb;6 Suppl 1:S67-75.

PMID:
10685663
49.

Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study.

Brewer GJ, Dick RD, Grover DK, LeClaire V, Tseng M, Wicha M, Pienta K, Redman BG, Jahan T, Sondak VK, Strawderman M, LeCarpentier G, Merajver SD.

Clin Cancer Res. 2000 Jan;6(1):1-10.

50.

Supportive care, pain management, and quality of life in advanced prostate cancer.

Esper P, Redman BG.

Urol Clin North Am. 1999 May;26(2):375-89. Review.

PMID:
10361560

Supplemental Content

Loading ...
Support Center